Results 241 to 250 of about 148,826 (294)

The potential for biased signalling in the P2Y receptor family of GPCRs

open access: yesBritish Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk   +2 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown   +2 more
wiley   +1 more source

Disrupting the ASH2L-DPY30 PPI in cancer: structure, function, and therapeutic opportunities in H3K4 methylation. [PDF]

open access: yesEpigenetics Chromatin
Kamel EM   +6 more
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Defining AV2‐1 as a novel pharmacological probe to target human and rodent TRPV2

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Transient receptor potential vanilloid 2 (TRPV2) is a non‐selective cation channel implicated in immune cell functions. However, progress in understanding TRPV2 has been limited by a lack of potent and selective pharmacological tools, particularly those targeting the human variant. We aimed to identify and characterise a
Andrea Leipe   +6 more
wiley   +1 more source

Structural insight into IscB's RNA-lid-based inactivation mechanism. [PDF]

open access: yesNat Struct Mol Biol
Wang F   +20 more
europepmc   +1 more source

The amino terminal domain of the human α7 nicotinic acetylcholine receptor subunit leads to the functional expression of human/insect receptors

open access: yesBritish Journal of Pharmacology, EarlyView.
Human α7 receptors have been characterised in terms of pharmacological properties. Insertion of the N‐terminal domain of the human α7 subunit leads to honeybee and cockroach chimeric receptors activated by ACh and inhibited by α‐Bgt. Insertion of the human cys‐loop leads to cockroach chimeric receptors modulated by PNU.
Alison Cartereau   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy